[CITATION][C] Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous …
M Shapiro, AH Rook, MS Lehrer… - Journal of the American …, 2002 - Elsevier
Bexarotene is a new selective retinoid X recep-tor agonist. Early trials demonstrated
significant antitumor responses in patients with cutaneous T-cell lymphoma (CTCL) who
were treated with this agent. We describe a patient with advanced Sézary syndrome and
large-cell transformation who achieved near-total disease resolution after the addition of
bexarotene and psoralen plus ultraviolet A (PUVA) to multimodality biologic response
modifier therapy.
significant antitumor responses in patients with cutaneous T-cell lymphoma (CTCL) who
were treated with this agent. We describe a patient with advanced Sézary syndrome and
large-cell transformation who achieved near-total disease resolution after the addition of
bexarotene and psoralen plus ultraviolet A (PUVA) to multimodality biologic response
modifier therapy.